Design, Synthesis, and Biological Evaluation of Novel Benzimidazole/Schiff Base Hybrid Derivatives With Potential Biological Activities
Archiv der Pharmazie · 2025-12 · 358 (12)
DOI: 10.1002/ardp.70165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 15.12.2025. Verfasst von Mohamed Y Abdel-Hady und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Badr University in Assiut (BUA), Asyut, Egypt. Hauptthemen laut MEDLINE: Benzimidazoles, Drug Design, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
A novel series of benzimidazole‐based derivatives (5a–g) , (6a–b) , and (7a–b) were designed, synthesized, and evaluated for their potential as dual inhibitors of EGFR and HER‐2. The synthesized compounds were subjected to in vitro screening against a panel of selected human cancer cell lines. Additionally, their cytotoxicity was assessed using normal human mammary epithelial cells (MCF‐10A) to evaluate their safety profile. Among the tested derivatives, compounds 5b, 5f , and 6a demonstrated the most pronounced antiproliferative activity, exhibiting IC₅₀ values of 6, 8, and 5 µM, respectively. These values reflect a potency at least fourfold greater than that of the reference drug Doxorubicin (IC₅₀ = 33 µM). EGFR and HER‐2 enzyme inhibition assays were conducted to explore the potential molecular targets responsible for the observed anticancer effects. Notably, compound 6a (R₁ = phenyl, thiosemicarbazide) exhibited superior efficacy against the MCF‐7 breast cancer cell line, with an IC₅₀ of 5 µM, approximately six times more potent than Doxorubicin. Conversely, compound 7b , with an IC₅₀ value of 85 µM against MCF‐7 cells, was the least active, underscoring the critical role of the phenyl moiety in antiproliferative activity. Furthermore, a molecular docking study was conducted to investigate the binding interactions of 6a within the active sites of EGFR and HER‐2, providing insight into its potential mechanism of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Badr University in Assiut (BUA), Asyut, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.
- Department of Chemistry, Faculty of Science, King Khalid University, Abha, Saudi Arabia.
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
ORCID-Profile: Mohamed Y Abdel-Hady, Martha M Morcoss, Bahaa G M Youssif
Zitieren
APA
Abdel-Hady, M. Y., Morcoss, M. M., Alzahrani, A. Y. A., Youssif, B. G. M., Abdelhafez, E. S. M. N., & Abdel-Aziz, M. (2025). Design, Synthesis, and Biological Evaluation of Novel Benzimidazole/Schiff Base Hybrid Derivatives With Potential Biological Activities. Archiv der Pharmazie, 358(12). https://doi.org/10.1002/ardp.70165
Vancouver
Abdel-Hady MY, Morcoss MM, Alzahrani AYA, Youssif BGM, Abdelhafez ESMN, Abdel-Aziz M. Design, Synthesis, and Biological Evaluation of Novel Benzimidazole/Schiff Base Hybrid Derivatives With Potential Biological Activities. Archiv der Pharmazie. 2025;358(12). doi:10.1002/ardp.70165
BibTeX
@article{AbdelHady2025,
author = {Abdel-Hady, Mohamed Y and Morcoss, Martha M and Alzahrani, Abdullah Yahya Abdullah and Youssif, Bahaa G M and Abdelhafez, El Shimaa M N and Abdel-Aziz, Mohamed},
title = {Design, Synthesis, and Biological Evaluation of Novel Benzimidazole/Schiff Base Hybrid Derivatives With Potential Biological Activities},
journal = {Archiv der Pharmazie},
year = {2025},
volume = {358},
number = {12},
doi = {10.1002/ardp.70165}
}
EUVIMED